Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
92.50    0.00 (0.00%)
Bid:
90.00
Ask:
95.00
Spread: 5.00 (5.556%)
Market Cap: £6.08m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Interim Results

28 Sep 2018 07:00

RNS Number : 2480C
Crimson Tide PLC
28 September 2018
Β 
28 September 2018 Β  Crimson Tide plc Β  ("Crimson Tide" or "the Company") Β  Interim Results for the six months ended 30 June 2018 Β  Crimson Tide, the provider of mpro5 - smart mobility as a service (AIM: TIDE.L), announces its unaudited interim results for the six months ended 30 June 2018. Β 

Highlights

Β 

Β· Strong growth in opportunities from planned Sales & Marketing investment

Β 

Β· Revenues up 8% up on 1H 2017 (Β£1,201k v Β£1,114k)

Β 

Β· Profit Before Tax Β£4k (1H 2017: Β£142k) after over Β£200k of planned investment

Β 

Β· IOT solution, 5Things, now ready for market, mpro5 publicly downloadable.

Β 

Β 

Β 

Barrie Whipp, Executive Chairman, commented,

Β 

"Our pipeline has grown significantly and have seen additional demand from Europe and the Middle East as well as in the UK & Ireland. The Board estimates that, considering increased investment in Sales & Marketing, like for like profit would have increased by approximately 50%. We are working on a much wider range of exciting opportunities and have developed mpro5's IOT capabilities. mpro5 is now publicly downloadable from app stores for demonstration purposes and for smaller businesses. We are extremely well placed to take advantage of the opportunities generated from our marketing activities and the Board is excited to accelerate our growth to the next level. "

Β 

Β 

Β 

Enquiries:

Β 

Crimson Tide plc

Barrie Whipp /Β Luke Jeffrey

Β 

01892 542444

Arden Partners

Steve Douglas / Dan Gee-Summons

Β 

020 7614 5900

Β  Β  Β  Β  Β  Chairman's Statement Β 

The first half of 2018 has been a period of continued investment in the Company, in line with the strategy set out in 2017 to accelerate future growth. We have increased our sales team and invested significantly in marketing and we are already seeing a step change in our pipeline of opportunities, both in terms of volume and scale as a result.

Β 

We currently have over 100 identified opportunities with potential clients, five times more than typical levels before these investments were made. These opportunities range from those in the SME sector to substantial enterprise clients. This has also enabled us to increase our base pricing.

Β 

Supporting this are the continued operational improvements that have been made to mpro5. One of our goals for mpro5 this year was to make it available as a publicly available download and this was achieved with our Project Apollo release. Potential clients can now simply register for a free trial, download mpro5 and start completing their flows immediately. This gives us confidence for our future offering, where mpro5 is available for Micro and Nano organisations globally on a shorter-term subscription basis.

Β 

This will be further supported in the coming months with the release of a new website which will provide an easier interface for direct users and will allow them to schedule workflows for themselves rather than doing so indirectly through our support team.

Β 

We have also made further progress with 5Things, our Internet of Things ("IoT") function which is now complete and ready for general sale. We believe we have a unique proposition whereby we can supply our own tested sensors and gateways, are network agnostic and can integrate existing client services. There has clearly been a lot of noise around IoT and its potential applications for some time but its use in sensors and resulting alerts is gaining widespread acceptance and traction. mpro5 can schedule complete workflows based upon sensor data and rules and, as such, we will be able to sell to sensor providers, not just end users of mpro5.

Β 

We continue to be excited about our new geographic areas of operation, particularly The Netherlands and Middle East as well as increased focus in Ireland. Our investment in these geographies has been sensible and measured. They have naturally taken their time to become established, but they now represent an increasing number of the opportunities that we are seeing. Further evidence of this was the announcement, post the period end, of two new contracts secured in the Middle East and a contract with a major US pharma company secured in Ireland. We have recently recruited Sam Roberts as our new Director of Enterprise Sales and two other sales-focused employees in Ireland and Dubai

Β 

We look forward to updating shareholders with further announcements as we secure more business from these geographies.

Β 

We remain on track to deliver the strategy set out to our shareholders at the start of 2017. With the increased functionality of mpro5 and 5Things and our increased sales capability, I believe that we are in a strong position to convert an increasing amount of the growing opportunities pipeline that our investment in marketing has afforded us. With high margins and sensible costs, we are optimistic in the current climate.

Β 

Β 

I believe that had we not made such investments then our profits would have increased by around 50% on a like for like basis. As it is, with this investment in place we are well placed to deliver accelerated, sustainable growth, underpinned by our healthy cash balance which will drive returns for shareholders in the years to come.

Β 

Β 

Barrie Whipp Executive Chairman 28 September 2018 Β  Β  Crimson Tide plc

Unaudited Consolidated Income Statement for the 6 months to 30 June 2018

Β 

Unaudited

6 Months

ended

30 June

2018

Unaudited

6 Months

ended

30 June

2017

Audited

12 Months

ended 31

December

2017

Β£000

Β£000

Β£000

Β 

Β 

Revenue

1,201

1,114

2,275

Β 

Cost of Sales

(170)

(109)

(231)

Β 

Β 

Gross Profit

1,031

1,005

2,044

Β 

Overhead expenses

(807)

(647)

(1,240)

Β 

Exceptional item (Note 2)

-

-

(44)

Β 

Β 

Earnings before interest, tax, depreciation & amortisation

Β 

224

Β 

358

Β 

760

Β 

Depreciation & Amortisation

(202)

(189)

(394)

Β 

Β 

Profit from operations

22

169

366

Β 

Interest payable and similar charges

(18)

(27)

(51)

Β 

Β 

Profit before taxation

4

142

315

Β 

Taxation

-

-

(5)

Β 

Β 

Profit for the year attributable to equity holders of the parent

Β 

4

Β 

142

Β 

310

Β 

Β 

Earnings per share

Unaudited

6 Months

ended

30 June

2018

Unaudited

6 Months

ended

30 June

2017

Audited

12 Months

ended 31

December

2017

Basic earnings per Ordinary Share

0.00p

0.03p

0.07p

Β 

Diluted earnings per Ordinary Share

0.00p

0.03p

0.07p

Β 

Β 

(see Note 3)

Β 

Β 

Β 

Β 

Β 

Unaudited Consolidated Statement of Comprehensive Income

for the 6 months to 30 June 2018

Β 

Unaudited

6 Months

ended

30 June

2018

Unaudited

6 Months

ended

30 June

2017

Audited

12 Months

ended 31

December

2017

Β£000

Β£000

Β£000

Β 

Β 

Profit for the period

4

142

310

Β 

Β 

Other comprehensive income/(loss) for period:

Β 

Exchange differences on translating foreign operations

(1)

(2)

(1)

Β 

Β 

Β 

Total comprehensive profit recognised in the period and attributable to equity holders of parent

Β 

3

Β 

140

Β 

309

Β 

Β 

Unaudited Consolidated Statement of Financial Position at 30 June 2018

Β 

Unaudited

As at

30 June

2018

Unaudited

As at

30 June

2017

Audited

As at 31 December 2017

Β£000

Β£000

Β£000

Fixed Assets

Intangible assets

1,785

1,592

1,698

Equipment, fixtures & fittings

491

698

611

2,276

2,290

2,309

Current Assets

Inventories

10

8

8

Trade and other receivables

787

686

974

Cash and cash equivalents

782

861

757

Total current assets

1,579

1,555

1,739

Total assets

3,855

3,845

4,048

Equity and liabilities

Equity

Share capital

454

453

454

Share premium

121

112

121

Other reserves

420

420

421

Reverse acquisition reserve

(5,244)

(5,244)

(5,244)

Retained earnings

7,073

6,901

7,069

Total Equity

2,824

2,642

2,821

Creditors

Amounts falling due within one year

754

831

868

Β 

Creditors

Amounts falling due after more than one year

277

372

359

Total liabilities

1,031

1,203

1,227

Total equity and liabilities

3,855

3,845

4,048

Β 

Β 

Unaudited Consolidated Statement of Changes In Equity at 30 June 2018

Β 

Β 

Β 

Share capital

Β 

Β 

Share premium

Β 

Β 

Other reserves

Reverse acquisi-tion reserve

Β 

Β 

Retained earnings

Β 

Β 

Β 

Total

Β£000

Β£000

Β£000

Β£000

Β£000

Β£000

Balance at 31 December 2016

453

112

422

(5,244)

6,759

2,502

Profit for the period

-

-

-

-

142

142

Translation movement

-

-

(2)

-

-

(2)

Balance at

30 June 2017

Β 

453

Β 

112

Β 

420

Β 

(5,244)

Β 

6,901

Β 

2,642

Balance at 31 December 2017

454

121

421

(5,244)

7,069

2,821

Profit for the period

-

-

-

-

4

4

Translation movement

-

-

(1)

-

-

(1)

Balance at

30 June 2018

Β 

454

Β 

121

Β 

420

Β 

(5,244)

Β 

7,073

Β 

2,824

Unaudited Consolidated Statement of Cashflows for the 6 months to 30 June 2018

Β 

Unaudited

6 Months

ended

30 June

2018

Unaudited

6 Months

ended

30 June

2017

Audited

12 Months

ended

31 December

2017

Β£000

Β£000

Β£000

Cash flows from operating activities

Profit before tax

4

142

315

Adjustments for:

Amortisation of Intangible Assets

71

56

120

Depreciation of equipment, fixtures and fittings

131

133

274

Net Interest

18

27

51

Operating cash flows before movement in working capital and provisions

224

358

760

Increase in inventories

(2)

(1)

(1)

Decrease/(increase) in trade and other receivables

187

(50)

(338)

(Decrease)/increase in trade and other payables

(48)

58

143

Cash generated from operations

361

365

564

Taxes paid

-

-

(5)

Net cash generated in operating activities

361

365

559

Cash flows used in investing activities

Purchase of fixed assets

(170)

(207)

(431)

Net cash used in investing activities

(170)

(207)

(431)

Cash flows from financing activities

Net proceeds from issues of shares

-

-

10

Interest paid

(18)

(27)

(51)

Net decrease in borrowings

(148)

(150)

(189)

Net cash used in financing activities

Β 

(166)

Β 

(177)

(230)

Net increase/(decrease) in cash and cash equivalents

25

(19)

(102)

Net cash and cash equivalents at beginning of period

757

859

859

Net cash and cash equivalents at end of period

782

840

757

Β 

Β 

Β 

Unaudited

6 Months

ended

30 June

2018

Unaudited

6 Months

ended

30 June

2017

Audited

12 Months

ended

31 December

2017

Β£000

Β£000

Β£000

Analysis of net funds:

Cash and cash equivalents

782

861

757

Bank overdraft

-

(21)

-

782

840

757

Other borrowings due within one year

(214)

(306)

(280)

Borrowings due after one year

(277)

(372)

(359)

Net funds

291

162

118

Β  Β  Β  Β  Crimson Tide Plc

Β 

Notes to the Unaudited Interim Results for the 6 months ended 30 June 2018

Β 

1. Basis of preparation of interim report

Β 

The information for the period ended 30 June 2018 does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. It has been prepared in accordance with the accounting policies set out in, and is consistent with, the audited financial statements for the twelve months ended 31 December 2017. A copy of the statutory accounts for that period has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain statements under Section 498 (2) or (3) of the Companies Act 2006.

Β 

Β 

2. Exceptional item

Β 

The exceptional item of Β£44,000 in the year to 31 December 2017 represents one-off legal fees and accounting due diligence costs incurred in preparation of an acquisition that was subsequently aborted by the Company.

Β 

Β 

3. Earnings per share

Β 

The calculation of the basic earnings per share is based on the profit attributable to ordinary shareholders and the weighted average number of ordinary shares in issue during the period.

Β 

The calculation of the diluted earnings per share is based on the profit per share attributable to ordinary shareholders and the weighted average number of ordinary shares that would be in issue, assuming conversion of all dilutive potential ordinary shares into ordinary shares.

Β 

Reconciliations of the profit and weighted average number of ordinary shares used in the calculation are set out below:

Β 

Β 

Β Unaudited

Β 6 Months

ended

30 June

2018

Β 

Β 

Unaudited

Β 6 Months

ended

30 June

2017

Β 

Β 

Audited

Β 12 Months

ended 31

December

2017

Β 

Earnings per share

Reported profit (Β£000)

4

142

310

Reported basic earnings per share (pence)

0.00

0.03

0.07

Reported diluted earnings per share (pence)

0.00

0.03

0.07

Β 

Β 

Unaudited

Β 6 Months

ended

30 June

2018

Β 

Β 

Unaudited

Β 6 Months

ended

30 June

2017

Β 

Β 

Audited

Β 12 Months

ended 31

December

2017

Β 

No. 000

No. 000

No. 000

Weighted average number of ordinary shares:

Shares in issue at start of period

454,486

453,486

453,486

Effect of shares issued during the period

-

-

52

Weighted average number of ordinary

Shares for basic EPS

Β 

454,486

Β 

453,486

Β 

453,538

Effect of share options outstanding

10,364

12,522

11,282

Weighted average number of ordinary

shares for diluted EPS

Β 

464,850

Β 

466,008

Β 

464,820

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
IR UBVBRWAAKUAR
Date   Source Headline
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company
23rd Apr 202110:37 amRNSPDMR Dealings
23rd Apr 202110:36 amRNSHolding(s) in Company
22nd Apr 202111:45 amRNSResult of General Meeting and Total Voting Rights
20th Apr 20217:00 amRNSContract Win
1st Apr 20213:52 pmRNSResult of Placing
1st Apr 202112:01 pmRNSPlacing to raise up to £6.0 million
1st Apr 202112:00 pmRNSPreliminary Results
18th Mar 20217:00 amRNSContract Win
1st Feb 20219:28 amRNSHolding(s) in Company
28th Jan 20217:00 amRNSAppointment of Director
26th Jan 20217:00 amRNSPilot with World Federation of Haemophilia
18th Jan 20219:36 amRNSHolding(s) in Company
12th Jan 20214:07 pmRNSHolding(s) in Company
7th Jan 20212:30 pmRNSHolding(s) in Company
23rd Dec 202012:15 pmRNSClarification re Grant of Options
22nd Dec 202010:45 amRNSGrant of Options under the Company's EMI Scheme
4th Dec 202011:35 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSContract Wins
12th Nov 20204:27 pmRNSDirector/PDMR Shareholding
6th Nov 20201:15 pmRNSPDMR dealing
26th Oct 202010:08 amRNSHolding(s) in Company
5th Oct 20209:16 amRNSHolding(s) in Company
18th Sep 20207:00 amRNSInterim Results
14th Sep 20202:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.